Karyopherin β3: A new cellular target for the HPV-16 E5 oncoprotein

Biochemical and Biophysical Research Communications

Volumn 371, Issue 4, 2008, Pages 684-688

  Krawczyk, Ewa ^a   Hanover, John A ^b   Schlegel, Richard ^a   Suprynowicz, Frank A ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

E5 oncoprotein; HPV 16; Karyopherin 3

Indexed keywords

CELL PROTEIN; HUMAN PAPILLOMAVIRUS TYPE 16 E5 PROTEIN; KARYOPHERIN BETA; ONCOPROTEIN; RIBOSOME PROTEIN; ONCOGENE PROTEIN E5, HUMAN PAPILLOMAVIRUS TYPE 16; RANBP5 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN COS1; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION; TARGET CELL; AMINO ACID SEQUENCE; ANIMAL; CERCOPITHECUS; GENETICS; METABOLISM; MOLECULAR GENETICS;

HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

AMINO ACID SEQUENCE; ANIMALS; BETA KARYOPHERINS; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL;

EID: 44149097342     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.122     Document Type: Article

References (35)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J.F., Peto J., Meijer C.J.L.M., and Munoz N. Human papillomaviruses is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
2. zur Hausen H., and de Villiers E.-M. Human papillomaviruses. Annu. Rev. Microbiol. 48 (1994) 424-447
3. Trottier H., and Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 24 (2006) 4-15
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. 2 (2002) 342-350
5. Bosch F.X., and de Sanjosé S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J. Natl. Cancer Inst. Monogr. 31 (2003) 3-13
6. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32 (2005) 16-24
7. Fehrmann F., and Laimins L.A. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22 (2003) 5201-5207
8. Longworth M.S., and A Laimins L. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68 (2004) 362-372
9. Münger K., and Howley P.M. Human papillomavirus immortalization and transformation functions 89 (2002) 213-228
10. Conrad M., Bubb V.J., and Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J. Virol. 67 (1993) 6170-6178
11. Disbrow G.L., Sunitha I., Baker C.C., Hanover J., and Schlegel R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology 311 (2003) 105-114
12. Suprynowicz F.A., Campo M.S., and Schlegel R. Biological activities of papillomavirus E5 protein. In: Campo M.S. (Ed). Papillomavirus Research: From Natural History to Vaccines and Beyond (2006), Caister Academic Press 97-113
13. Genther Williams S.M., Disbrow G.L., Schlegel R., Lee D., Threadgill D.W., and Lambert P.F. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 65 (2005) 6534-6542
14. Suprynowicz F.A., Disbrow G.L., Krawczyk E., Simic V., Lantzky K., and Schlegel R. HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 27 (2008) 1071-1078
15. +-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene 19 (2000) 3727-3732
16. Ashrafi G.H., Haghshenas M., Marchetti B., and Campo M.S. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int. J. Cancer 119 (2006) 2105-2112
17. Chen S.L., Lin S.T., Tsai T.C., Hsiao W.C., and Tsao Y.P. ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein. Oncogene 26 (2006) 42-53
18. Yaseen N.R., and Blobel G. Cloning and characterization of human karyopherin β3. Proc. Natl. Acad. Sci. USA 94 (1997) 4451-4456
19. Wozniak R.W., Rout M.P., and Aitchison J.D. Karyopherins and kissing cousins. Trends Cell Biol. 8 (1998) 184-188
20. Harel A., and Forbes D.J. Importin beta: conducting a much larger cellular symphony. Mol. Cell 16 (2004) 319-330
21. Jäkel S., and Görlich D. Importinβ, transportin, RanBP5 and RanBP7 mediate nuclear import of ribosomal proteins in mammalian cells. EMBO J. 17 (1998) 4491-4502
22. Deane R., Schäfer W., Zimmermann H.P., Mueller L., Görlich D., Prehn S., Ponstingl H., and Bischoff F.R. Ran-binding protein 5 (RanBP5) is related to the nuclear transport factor importin-beta but interacts differently with RanBP1. Mol. Cell. Biol. 17 (1997) 5087-5096
23. Morgenstern J.P., and Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18 (1990) 3587-3596
24. Disbrow G.L., Hanover J.A., and Schlegel R. Endoplasmic reticulum-localized human papillomavirus type 16 E5 protein alters endosomal pH but not trans-Golgi pH. J. Virol. 79 (2005) 5839-5846
25. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90 (1993) 8392-8396
26. Sparkowski J., Anders J., and Schlegel R. Mutation of the bovine papillomavirus E5 oncoprotein at amino acid 17 generates both high- and low-transforming variants. J. Virol. 68 (1994) 6120-6123
27. Lim P.S., Jenson A.B., Cowsert L., Nakai Y., Lim L.Y., Jin X.W., and Sundberg JP J.P. Distribution and specific identification of papillomavirus major capsid protein epitopes by immunocytochemistry and epitope scanning of synthetic peptides. J. Infect. Dis. 162 (1990) 1263-1269
28. Baege A.C., Berger A., Schlegel R., Veldman T., and Schlegel R. Cervical epithelial cells transduced with the papillomavirus E6/E7 oncogenes maintain stable levels of oncoprotein expression but exhibit progressive, major increases in hTERT gene expression and telomerase activity. Am. J. Pathol. 160 (2002) 1251-1257
29. Suprynowicz F.A., Disbrow G.L., Simic V., and Schlegel R. Are transforming properties of the bovine papillomavirus E5 protein shared by E5 from high-risk human papillomavirus type 16?. Virology 332 (2005) 102-113
30. Suprynowicz F.A., Sparkowski J., Baege A., and Schlegel R. E5 oncoprotein mutants activate phosphoinositide 3-kinase independently of platelet-derived growth factor receptor activation. J. Biol. Chem. 275 (2000) 5111-5119
31. Suprynowicz F.A., Baege A., Sunitha I., and Schlegel R. c-Src activation by the E5 oncoprotein enables transformation independently of PDGF receptor activation. Oncogene 21 (2002) 1695-1706
32. Darshan M.S., Lucchi J., Harding E., and Moroianu J. The L2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. J. Virol. 78 (2004) 12179-12188
33. Bordeaux J., Forte S., Harding E., Darshan M.S., Klucevsek K., and Moroianu J. The L2 minor capsid protein of low-risk human papillomavirus type 11 interacts with host nuclear import receptors and viral DNA. J. Virol. 80 (2006) 8259-8262
34. Thomsen P., van Deurs B., Norrild B., and Kayser L. The HPV 16 E5 oncogene inhibits endocytic trafficking. Oncogene 19 (2000) 6023-6032
35. Hajdu S.I. A note from history: the link between koilocytes and human papillomaviruses. Ann. Clin. Lab. Sci. 36 (2006) 485-487